Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Interest & Investment Income (2022 - 2026)

Elicio Therapeutics filings provide 2 years of Interest & Investment Income readings, the most recent being $75000.0 for Q4 2023.

  • On a quarterly basis, Interest & Investment Income rose 36.36% to $75000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $370000.0, a N/A change, with the full-year FY2023 number at $373000.0, up 473.85% from a year prior.
  • Interest & Investment Income hit $75000.0 in Q4 2023 for Elicio Therapeutics, down from $246000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $246000.0 in Q3 2023 to a low of $10000.0 in Q3 2022.